Medical Equipment

Global Transmucosal Drug Delivery Devices Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

March 17, 2026March 17, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Transmucosal Drug Delivery Devices Market At The End Of The 2026–2030 Forecast Period?

The transmucosal drug delivery devices market has seen substantial expansion in recent years. It is anticipated to expand from $54.63 billion in 2025 to $59.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. This historical growth is primarily due to the rise of non-invasive drug delivery methods, increased need for pain management therapies, broader application of hormone replacement treatments, innovations in pharmaceutical formulation, and a wider embrace of transmucosal therapies.

The transmucosal drug delivery devices market is anticipated to experience substantial growth in the upcoming years. It is expected to expand to **$81.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%**. This projected growth throughout the forecast period stems from the increasing progress in personalized medicine solutions, a rise in investments towards sophisticated drug delivery platforms, a burgeoning need for at-home drug administration devices, the expanding applications of biologics and peptide-based drugs, and an uptick in regulatory approvals for innovative delivery systems. Significant trends during this period involve the rising adoption of buccal and sublingual delivery formats, an increasing demand for rapid onset drug administration, the proliferation of microneedle and active delivery technologies, a heightened emphasis on patient-friendly drug delivery devices, and an enhanced focus on achieving dose accuracy and bioavailability.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

What Primary Drivers Are Shaping The Development Of The Transmucosal Drug Delivery Devices Market?

The transmucosal drug delivery devices market is anticipated to expand due to the increasing prevalence of chronic diseases. A chronic disease is defined as a long-term condition that typically progresses slowly and persists over time, often requiring continuous medical management to control symptoms and prevent complications. The rise in chronic diseases is influenced by lifestyle factors, aging populations, environmental factors, challenges within healthcare systems, and urbanization. Transmucosal drug delivery devices are utilized in chronic diseases to facilitate controlled and efficient medication delivery, ensuring sustained therapeutic levels for symptom management and improved patient adherence. For instance, according to the National Health Service, a UK-based government department, in June 2024, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, which was an 18% increase from 3,065,825 cases in 2022. Consequently, the growing occurrence of chronic diseases is a significant driver for the transmucosal drug delivery devices market.

What Segment Types Make Up The Transmucosal Drug Delivery Devices Market?

The transmucosal drug delivery devices market covered in this report is segmented –

1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices

2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

Subsegments:

1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films

2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays

3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators

4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels

5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels

Which Market Trends Are Creating New Opportunities In The Transmucosal Drug Delivery Devices Market?

Major companies involved in transmucosal drug delivery devices are developing innovative smart platforms, such as proprietary transdermal patch delivery systems, that enhance drug absorption while improving patient compliance and convenience. These proprietary transdermal patch delivery platforms are specialized technologies owned by companies for administering medications through the skin, ensuring controlled release and enhanced therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, launched STARSILON, a novel proprietary transdermal patch delivery platform, designed for a longer duration to achieve therapeutic delivery of difficult-to-formulate APIs. This expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.

Who Are The Key Players Driving Competition In The Transmucosal Drug Delivery Devices Market?

Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd

Read the full transmucosal drug delivery devices market report here:

https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

How Does The Transmucosal Drug Delivery Devices Market Perform Across Major Global Regions?

North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Transmucosal Drug Delivery Devices Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2026, By The Business Research Company

Oral Transmucosal Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report

Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795